Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
418 USD | +0.17% | +0.55% | +2.73% |
Mar. 21 | Vertex Pharmaceuticals Gets FDA Approval for VX-407's Investigational New Drug Application to Treat Kidney Disease | MT |
Mar. 21 | Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease | DJ |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock
- Equities
- Stock Vertex Pharmaceuticals Incorporated - Nasdaq
- Revisions Vertex Pharmaceuticals Incorporated